VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 75 filers reported holding VAXCYTE INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $29,714,662 | -51.4% | 582,869 | -52.4% | 0.02% | -50.0% |
| Q2 2023 | $61,130,156 | +124060.0% | 1,224,072 | -6.8% | 0.03% | +7.1% |
| Q1 2023 | $49,235 | -15.8% | 1,313,642 | +7.7% | 0.03% | -12.5% |
| Q4 2022 | $58,475 | -99.7% | 1,219,491 | +55.1% | 0.03% | +190.9% |
| Q3 2022 | $18,872,000 | +53.2% | 786,322 | +38.9% | 0.01% | +37.5% |
| Q2 2022 | $12,319,000 | +94.2% | 566,116 | +115.5% | 0.01% | +166.7% |
| Q1 2022 | $6,345,000 | -6.9% | 262,720 | -8.2% | 0.00% | 0.0% |
| Q4 2021 | $6,812,000 | -4.5% | 286,323 | +1.8% | 0.00% | -25.0% |
| Q3 2021 | $7,136,000 | +0.5% | 281,284 | -10.9% | 0.00% | 0.0% |
| Q2 2021 | $7,104,000 | +1.8% | 315,613 | -10.7% | 0.00% | -20.0% |
| Q1 2021 | $6,981,000 | -38.3% | 353,454 | -17.0% | 0.01% | -37.5% |
| Q4 2020 | $11,314,000 | +139.5% | 425,824 | +345.1% | 0.01% | +33.3% |
| Q3 2020 | $4,724,000 | -82.8% | 95,660 | -89.0% | 0.01% | -84.2% |
| Q2 2020 | $27,448,000 | – | 868,318 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 1,049,893 | $53,523,545 | 17.09% |
| Pivotal bioVenture Partners Investment Advisor LLC | 793,036 | $40,429,128 | 16.12% |
| Kynam Capital Management, LP | 1,302,407 | $66,396,709 | 10.86% |
| RA Capital Management | 7,891,254 | $402,296,129 | 7.92% |
| COMMODORE CAPITAL LP | 1,100,000 | $56,078,000 | 6.56% |
| GREAT POINT PARTNERS LLC | 531,211 | $27,081,137 | 4.93% |
| ACUTA CAPITAL PARTNERS, LLC | 121,022 | $6,169,702 | 4.14% |
| Frazier Life Sciences Management, L.P. | 1,164,405 | $59,361,367 | 3.94% |
| Novo Holdings A/S | 845,000 | $43,078,100 | 3.18% |
| BRAIDWELL LP | 1,619,553 | $82,564,812 | 2.61% |